BIOCAPS project targets TB

Skip to Navigation

Blog Post

  • Published: May 4, 2015
  • Author: Steve Down
  • Channels: Gas Chromatography / HPLC / Proteomics & Genomics / Ion Chromatography / Sample Preparation / Detectors / Electrophoresis / Laboratory Informatics / Base Peak / X-ray Spectrometry / Chemometrics & Informatics / Infrared Spectroscopy / UV/Vis Spectroscopy / Raman / Proteomics / NMR Knowledge Base / MRI Spectroscopy / Atomic

View comments on this post

The four-year BIOCAPS project set up by the EU in 2013 is making progress on several fronts, including a new vaccine for tuberculosis.

BIOCAPS is centred at the Institute of Biomedical Research of Vigo in Spain and is targeting tuberculosis, a lethal disease that kills an estimated 1.5 million people each year. Although a vaccine exists, it is ineffective against pulmonary tuberculosis, which is the most common form of the disease.

The research project will look to design a new vaccine while searching for biomarkers in the body that will help to reveal how effective the vaccine is. Currently, there is no valid biomarker for tuberculosis which makes it more difficult to test new vaccine candidates.

The project will also attempt to find out why some people are infected with the disease and others are not. "Understanding their immune system and how it is controlled could help achieve a more effective prophylactic therapy," explained África González-Fernández, co-ordinator of BIOCAPS.


There are currently no comments on this post.

Comment Form

You have to log in to comment on this post.

Log in using the form at the top of the page or register here.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved